Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Conatus Pharmaceuticals Inc. (NASDAQ: CNAT).

Full DD Report for CNAT

You must become a subscriber to view this report.


Recent News from (NASDAQ: CNAT)

Novartis In Liver Diseases NASH And PBC: A Look At The Bright Side
There can be no greater gift than that of giving one’s time and energy to help others without expecting anything in return. —Nelson Mandela Novartis AG (NVS) is a Swiss (Basel, Switzerland) multibillion biopharmaceutical company with a market cap of $178B and a broad the...
Source: SeekingAlpha
Date: May, 17 2018 14:35
Lipotoxicity And NASH: Gilead's Actions Speak Louder Than Words
I never lose. I either win or learn. —Nelson Mandela Gilead Sciences (GILD) is a multibillion ($89B market cap) biopharmaceutical company that has and is still revolutionizing the infectious disease market with innovative anti-viral therapies for HIV/AIDS, Hep B and C. It seem...
Source: SeekingAlpha
Date: May, 09 2018 11:08
Lucky Seven: Omeros Moves, Array Biopharma May Be Next
iShares Nasdaq Biotechnology ETF ( IBB ) was good for a 0.3% gain within the last three trading days, while the Lucky Seven netted a 2.6% gain. The Lucky Seven portfolio assumes an investor made a $1000 investment, to begin, in each pick. So, the portfolio began with $7,000. Lucky Seven ...
Source: SeekingAlpha
Date: May, 08 2018 15:02
Lucky Seven: An Introduction To My Top Biotechnology Picks
Introduction I am a Registered Nurse, currently advancing my education at Purdue University. I work on an intermediate care unit in a hospital where I am responsible for the care and lives of folks who come to me with a myriad of medical conditions. I hope to soon become a nursing professor....
Source: SeekingAlpha
Date: May, 03 2018 05:28
Conatus Pharmaceuticals' (CNAT) CEO Steve Mento on Q1 2018 Results - Earnings Call Transcript
Conatus Pharmaceuticals (CNAT) Q1 2018 Earnings Conference Call May 2, 2018 4:30 PM ET Executives Alan Engbring - Executive Director of Investor Relations and Corporate Communications Steven Mento - President and Chief Executive Officer Keith Marshall - Executive Vice President, ...
Source: SeekingAlpha
Date: May, 02 2018 21:16
Conatus Pharmaceuticals EPS in-line, beats on revenue
Conatus Pharmaceuticals (NASDAQ: CNAT ): Q1 EPS of -$0.17 in-line. More news on: Conatus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 02 2018 16:10
Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2018, and provided updates on its dev...
Source: GlobeNewswire
Date: May, 02 2018 16:05
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay
Karyopharm (KPTI) slumped 17% in the pre-market yesterday, ahead of data from a mid stage study of selinexor in treatment-resistant multiple myeloma. A couple of years ago, this same drug was pitted against Darzalex in the same indication and showed similar efficacy. An FDA filing was planned ...
Source: SeekingAlpha
Date: May, 02 2018 08:00
Conatus completes enrollment in mid-stage study of emricasan in NASH cirrhosis; shares ahead 1%
Conatus Pharmaceuticals ( CNAT +1.2% ) is up on below-average volume on the heels of its announcement that it has completed enrollment in its Phase 2b ENCORE-PH study assessing emricasan in patients with NASH cirrhosis and severe portal hypertension. More news on: Conatus Pharmaceuti...
Source: SeekingAlpha
Date: April, 30 2018 12:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-253.683.713.803.63243,769
2018-05-243.703.6553.723.62137,516
2018-05-233.713.70753.783.66121,612
2018-05-223.783.743.783.71126,562
2018-05-213.833.7453.853.72274,907

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2527,98298,16828.5042Cover
2018-05-2426,62675,71635.1656Short
2018-05-2321,56456,08338.4502Short
2018-05-2241,55877,36653.7161Short
2018-05-2161,798115,34253.5781Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CNAT.


About Conatus Pharmaceuticals Inc. (NASDAQ: CNAT)

Logo for Conatus Pharmaceuticals Inc. (NASDAQ: CNAT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CNAT)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 04 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 09 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 06 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 05 2018
      Annual statement of changes in beneficial ownership of securities
      Filing Type: 5Filing Source: edgar
      Filing Date: February, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: CNAT)

      Daily Technical Chart for (NASDAQ: CNAT)


      Stay tuned for daily updates and more on (NASDAQ: CNAT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CNAT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CNAT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CNAT and does not buy, sell, or trade any shares of CNAT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/